To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene SMARCC1TABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
293 supporting clones for gene SMARCC1 back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
CB989161 Human Placenta, placenta .a 1 to 618 20 to 639   tiling clone,   620/851
(72 %)
13 diff
(98.5 %id)
BC012101 Eye, retinoblastoma .a 11 to 2581 1 to 2571   available from MGC, AAA Internal priming: the 3' end of the oligo dT primed clone lies in the CDS 2571/2573
(99 %)
6 diff
(99.8 %id)
NM_003074.3   .a 11 to 5766 1 to 5756 exact RefSeq, AAA Possibly primed on the genome, locally A rich (11/12 A in genome downstream of last aligned base) 5756/5756
(100 %)
0 diff
(100 %id)
BC032564 Eye, retinoblastoma .a 37 to 2572 11 to 2546   available from MGC, AAA Internal priming: the 3' end of the oligo dT primed clone lies in the CDS 2536/2536
(100 %)
4 diff
(99.9 %id)
BX281013 eye, retinoblastoma .a 38 to 523 1 to 486       486/486
(100 %)
0 diff
(100 %id)
BC065253 Eye, retinoblastoma .a 42 to 2572 1 to 2531   available from MGC, AAA Internal priming: the 3' end of the oligo dT primed clone lies in the CDS 2531/2539
(99 %)
2 diff
(100.0 %id)
BU187458 eye, retinoblastoma .a 43 to 894 24 to 880   available from MGC,   857/890
(96 %)
14 diff
(98.5 %id)
CR991061 T-Lymphocytes .a 50 to 967 22 to 940       919/940
(97 %)
8 diff
(99.2 %id)
DA756819   .a 56 to 604 2 to 551   capped   550/550
(100 %)
1 diff
(99.9 %id)
TI_1243022481   .a 57 to 1167 40 to 1144       1105/1217
(90 %)
34 diff
(97.3 %id)
TI_1243022483   .a 57 to 1031 39 to 1006       966/1162
(83 %)
18 diff
(98.5 %id)
TI_1243022975   .a 57 to 1046 44 to 1034       991/1256
(78 %)
10 diff
(99.3 %id)
BC113465 Brain, cerebral cortex, PCR rescued clones .a 63 to 3486 1 to 3424 exact     3424/3424
(100 %)
0 diff
(100 %id)
BC117213 Brain, cerebral cortex, PCR rescued clones .a 63 to 3486 1 to 3424 exact     3424/3424
(100 %)
0 diff
(100 %id)
BC021862 Cervix, carcinoma .a 74 to 2581 1 to 2507   available from MGC, AAA Internal priming: the 3' end of the oligo dT primed clone lies in the CDS 2507/2508
(99 %)
5 diff
(99.9 %id)
U66615   .a 74 to 5273 1 to 5190 S19F I21D A22S T497S F528G ...     5190/5190
(100 %)
35 diff
(99.4 %id)
DA778803 brain .a 76 to 646 2 to 572   capped   571/571
(100 %)
0 diff
(100 %id)
DB066106 testis .a 76 to 626 2 to 552   capped   551/551
(100 %)
0 diff
(100 %id)
BC050564 Uterus, leiomyosarcoma .a 82 to 4408 1 to 4327 A39D tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 4327/4327
(100 %)
3 diff
(100.0 %id)
BJ990981 hepatoblastoma .a 92 to 671 1 to 580       580/580
(100 %)
0 diff
(100 %id)
CR988761 T-Lymphocytes .a 104 to 763 1 to 660       660/660
(100 %)
0 diff
(100 %id)
BC039843 Testis, embryonal carcinoma .a 107 to 2572 1 to 2466   available from MGC, AAA Internal priming: the 3' end of the oligo dT primed clone lies in the CDS 2466/2474
(99 %)
2 diff
(100.0 %id)
BG257746 embryonal carcinoma, cell line, testis .a 108 to 774 1 to 671   available from MGC,   671/881
(76 %)
5 diff
(99.5 %id)
CR746454 embryonal carcinoma, cell line, testis .a 114 to 622 10 to 518       509/518
(98 %)
6 diff
(98.9 %id)
CT001462 T-Lymphocytes .a 117 to 965 1 to 848       848/853
(99 %)
6 diff
(99.3 %id)
CB995151 placenta, pre-eclamptic placenta .a 121 to 889 29 to 800       772/800
(96 %)
13 diff
(98.4 %id)
BU153608 eye, retinoblastoma .a 134 to 921 1 to 797       797/849
(93 %)
10 diff
(98.9 %id)
BU171578 melanotic melanoma, skin .a 303 to 1173 1 to 869       869/927
(93 %)
8 diff
(99.2 %id)
AW502835 lymph .a 385 to 862 8 to 485       478/485
(98 %)
6 diff
(98.8 %id)
TI_154158534   .a 385 to 922 80 to 616       537/614
(87 %)
8 diff
(98.7 %id)
DA713873   .a 402 to 902 2 to 502   capped   501/501
(100 %)
0 diff
(100 %id)
TI_1320133249   .a 437 to 1481 1059 to 8       1052/1107
(95 %)
36 diff
(96.8 %id)
BP282714 bone marrow .a 455 to 1036 1 to 582       582/582
(100 %)
0 diff
(100 %id)
DA745705   .a 457 to 1024 2 to 569   capped   568/568
(100 %)
0 diff
(100 %id)
CN272350 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .a 495 to 1181 1 to 687       687/687
(100 %)
0 diff
(100 %id)
CN272316 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 558 to 902 1 to 345       345/345
(100 %)
0 diff
(100 %id)
BP364490 lung .a 584 to 1165 1 to 582       582/582
(100 %)
0 diff
(100 %id)
CN272320 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 597 to 1371 1 to 775       775/775
(100 %)
0 diff
(100 %id)
CA406844 adipose .a 614 to 1257 1 to 643       643/643
(100 %)
7 diff
(99.0 %id)
AU118690 whole embryo, mainly head .a 621 to 1359 2 to 740   capped   739/739
(100 %)
1 diff
(99.9 %id)
BF095571 uterus_tumor .a 657 to 964 308 to 1       308/308
(100 %)
0 diff
(100 %id)
CN272334 embryonic stem cells, cell lines H1, H7, andH9 .a 738 to 1331 1 to 594       594/594
(100 %)
0 diff
(100 %id)
TI_1243019049   .a 750 to 1881 11 to 1134       1126/1225
(91 %)
20 diff
(98.4 %id)
AU136872 placenta .a 773 to 1515 2 to 751   capped   750/834
(89 %)
15 diff
(98.3 %id)
BU845008 ovary, teratocarcinoma, cell line .a 780 to 1584 1 to 811       811/921
(88 %)
9 diff
(99.1 %id)
BU845740 ovary, teratocarcinoma, cell line .a 780 to 1585 1 to 806       806/945
(85 %)
2 diff
(99.8 %id)
BU846170 ovary, teratocarcinoma, cell line .a 780 to 1634 1 to 857       857/867
(98 %)
5 diff
(99.5 %id)
BU859389 ovary, teratocarcinoma, cell line .a 780 to 1659 1 to 888       888/898
(98 %)
13 diff
(98.6 %id)
BU931025 ovary, teratocarcinoma, cell line .a 780 to 1676 1 to 913       913/925
(98 %)
20 diff
(97.9 %id)
BP228453   .a 823 to 1405 1 to 583       583/583
(100 %)
0 diff
(100 %id)
DA441287 tongue, tumor tissue .a 824 to 1409 2 to 587   capped   586/586
(100 %)
0 diff
(100 %id)
TI_154149151   .a 826 to 1546 65 to 785       721/721
(100 %)
19 diff
(97.4 %id)
CF137531 lymph .a 832 to 1260 8 to 436       429/436
(98 %)
0 diff
(100 %id)
TI_154167017   .a 832 to 1511 89 to 770       682/822
(82 %)
19 diff
(97.7 %id)
DA619017   .a 838 to 1424 2 to 588   capped   587/587
(100 %)
0 diff
(100 %id)
BP252901 Kidney .a 874 to 1455 1 to 582       582/582
(100 %)
0 diff
(100 %id)
AU130346   .a 874 to 1345 2 to 473   capped   472/472
(100 %)
3 diff
(99.4 %id)
BP253750 Kidney .a 885 to 1466 1 to 582       582/582
(100 %)
0 diff
(100 %id)
BQ887896 brain, neuroblastoma, cell line .a 915 to 1700 1 to 792       792/955
(82 %)
16 diff
(98.4 %id)
TI_1243019045   .a 918 to 2115 21 to 1198       1186/1225
(96 %)
36 diff
(97.1 %id)
BM836628 Ascites, stomach .a 962 to 1431 1 to 470       470/470
(100 %)
0 diff
(100 %id)
TI_154150900   .a 1022 to 1513 83 to 574       492/637
(77 %)
9 diff
(98.6 %id)
TI_154160835   .a 1080 to 1653 84 to 657       574/574
(100 %)
5 diff
(99.2 %id)
CD616216   .a 1108 to 1773 8 to 673       666/674
(98 %)
7 diff
(99.0 %id)
TI_154165870   .a 1112 to 1581 80 to 549       470/470
(100 %)
0 diff
(100 %id)
CB135929 Liver .a 1144 to 1718 1 to 575       575/575
(100 %)
0 diff
(100 %id)
BP357264 mammary gland .a 1200 to 1781 1 to 582       582/582
(100 %)
0 diff
(100 %id)
TI_154158207   .a 1208 to 1757 87 to 636       550/550
(100 %)
0 diff
(100 %id)
BU191789 embryonal carcinoma, cell line, testis .a 1220 to 1971 1 to 760       760/921
(82 %)
24 diff
(97.4 %id)
DC324482 brain .a 1265 to 1855 1 to 592       592/596
(99 %)
3 diff
(99.5 %id)
TI_154167200   .a 1278 to 1894 79 to 701       621/852
(72 %)
20 diff
(97.7 %id)
DC366800   .a 1290 to 1852 1 to 563       563/563
(100 %)
0 diff
(100 %id)
CN272349 embryonic stem cells, DMSO-treated H9 cellline .a 1293 to 1949 1 to 657       657/657
(100 %)
0 diff
(100 %id)
TI_1243019043   .a 1353 to 2452 16 to 1107       1092/1240
(88 %)
18 diff
(98.6 %id)
DC300240   .a 1365 to 1937 1 to 573       573/573
(100 %)
0 diff
(100 %id)
TI_154165583   .a 1390 to 1964 110 to 684       577/859
(67 %)
14 diff
(98.4 %id)
BM806815 lymph, lymphoma, cell line .a 1393 to 2429 1 to 1050       1050/1051
(99 %)
42 diff
(96.1 %id)
FN140973 breast carcinoma .a 1439 to 1507 1 to 67       67/67
(100 %)
3 diff
(95.6 %id)
BQ424040 eye, retinoblastoma .a 1526 to 2296 20 to 794       775/855
(90 %)
17 diff
(98.1 %id)
TI_154157377   .a 1531 to 2020 78 to 567       490/490
(100 %)
0 diff
(100 %id)
DC329102 corpus callosum .a 1554 to 2112 1 to 561       559/561
(99 %)
4 diff
(99.3 %id)
DC372098   .a 1556 to 2097 1 to 542       542/542
(100 %)
0 diff
(100 %id)
BU159991 eye, retinoblastoma .a 1565 to 2429 12 to 880       869/891
(97 %)
15 diff
(98.4 %id)
AK302412 testis .a 1567 to 3539 1 to 1973       1973/1973
(100 %)
3 diff
(99.9 %id)
DC400037 testis .a 1567 to 2141 1 to 575       575/575
(100 %)
0 diff
(100 %id)
BC040242 Placenta, choriocarcinoma .a 1579 to 5766 1 to 4189   tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (11/12 A in genome downstream of last aligned base) 4189/4189
(100 %)
2 diff
(100.0 %id)
TI_154151698   .a 1586 to 2022 87 to 523       437/445
(98 %)
9 diff
(98.0 %id)
AL040632 testis .a 1592 to 2026 1 to 432     Possibly primed on the genome, locally A rich (11/11 A in genome downstream of last aligned base) 432/432
(100 %)
5 diff
(98.9 %id)
TI_154148940   .a 1612 to 2344 68 to 805       738/740
(99 %)
15 diff
(98.0 %id)
TI_154150762   .a 1612 to 2287 80 to 753       674/782
(86 %)
21 diff
(97.4 %id)
DC373461 tongue .a 1646 to 2216 1 to 572       572/572
(100 %)
2 diff
(99.7 %id)
FN102629 breast carcinoma .a 1656 to 1764 1 to 107       107/107
(100 %)
2 diff
(98.2 %id)
BG254858 adenocarcinoma, cell line, Prostate .a 1677 to 2448 1 to 778       778/878
(88 %)
18 diff
(98.0 %id)
DC384941   .a 1679 to 2224 1 to 546       546/546
(100 %)
0 diff
(100 %id)
DC351087 brain .a 1691 to 2279 1 to 589       589/589
(100 %)
1 diff
(99.9 %id)
AW504753 lymph .a 1692 to 2114 8 to 430       423/430
(98 %)
0 diff
(100 %id)
TI_154161014   .a 1692 to 2286 71 to 664       594/727
(81 %)
12 diff
(98.4 %id)
TI_154159424   .a 1699 to 2287 89 to 669       581/652
(89 %)
19 diff
(97.1 %id)
FN108016 breast carcinoma .a 1707 to 1826 121 to 1     Submitted on the opposite strand 121/121
(100 %)
1 diff
(99.2 %id)
DB072180 testis .a 1734 to 2276 2 to 544   capped   543/543
(100 %)
0 diff
(100 %id)
TI_1243018961   .a 1816 to 2987 1 to 1168       1168/1270
(91 %)
14 diff
(98.9 %id)
FN053600 breast carcinoma .a 1901 to 1971 73 to 4     Submitted on the opposite strand 70/74
(94 %)
0 diff
(100 %id)
BP369244 testis .a 1904 to 2485 1 to 582       582/582
(100 %)
0 diff
(100 %id)
FN098348 breast carcinoma .a 1910 to 2015 1 to 104       104/104
(100 %)
4 diff
(96.2 %id)
DB292425 uterus .a 1925 to 2514 2 to 591   capped   590/590
(100 %)
0 diff
(100 %id)
DB214207 trachea .a 1938 to 2506 2 to 570   capped   569/569
(100 %)
0 diff
(100 %id)
CN272315 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 1984 to 2339 1 to 356       356/356
(100 %)
0 diff
(100 %id)
BJ990982 hepatoblastoma .a 2006 to 2545 540 to 1       540/540
(100 %)
0 diff
(100 %id)
FN068896 breast carcinoma .a 2012 to 2113 1 to 102       102/104
(98 %)
1 diff
(99.1 %id)
AU145193 whole embryo, mainly head .a 2026 to 2565 540 to 1       540/565
(95 %)
4 diff
(99.3 %id)
TI_149275263   .a 2060 to 2572 580 to 69   AAA Internal priming: the 3' end of the oligo dT primed clone lies in the CDS 512/737
(69 %)
2 diff
(99.8 %id)
BQ440477 leiomyosarcoma, uterus .a 2075 to 2906 1 to 839       839/886
(94 %)
15 diff
(98.4 %id)
DC403205 testis .a 2111 to 2665 1 to 551       551/553
(99 %)
7 diff
(98.8 %id)
TI_154152623   .a 2113 to 2618 80 to 585       506/512
(98 %)
4 diff
(99.3 %id)
BG260186 bladder, transitional cell papilloma, cell line .a 2120 to 2902 1 to 782       782/791
(98 %)
17 diff
(97.9 %id)
BU171528 melanotic melanoma, skin .a 2123 to 2997 1 to 873       873/873
(100 %)
4 diff
(99.6 %id)
FN077759 breast carcinoma .a 2124 to 2215 92 to 1     Submitted on the opposite strand 92/93
(98 %)
0 diff
(100 %id)
AI093415 uterus .a 2124 to 2619 496 to 1       496/496
(100 %)
0 diff
(100 %id)
AA600334   .a 2146 to 2566 421 to 1       421/421
(100 %)
0 diff
(100 %id)
BP237547 Liver .a 2155 to 2774 1 to 620       620/629
(98 %)
1 diff
(99.9 %id)
FN120376 breast carcinoma .a 2183 to 2263 79 to 1     Submitted on the opposite strand 79/80
(98 %)
2 diff
(97.5 %id)
AU156906 placenta .a 2218 to 2557 340 to 1       340/340
(100 %)
6 diff
(98.3 %id)
AL046313 testis .a 2223 to 3018 1 to 798       798/800
(99 %)
3 diff
(99.7 %id)
AL045873 testis .a 2223 to 2489 1 to 267       267/267
(100 %)
0 diff
(100 %id)
BF059106 fibrotheoma, ovary .a 2235 to 2531 1 to 297     Submitted on the opposite strand 297/297
(100 %)
0 diff
(100 %id)
TI_1243018955   .a 2275 to 3441 13 to 1171       1159/1247
(92 %)
10 diff
(99.2 %id)
TI_1320133245   .a 2288 to 3253 964 to 2       963/967
(99 %)
3 diff
(99.7 %id)
BQ961807 epithelioid carcinoma cell line, Pancreas .a 2297 to 3173 1 to 877       877/877
(100 %)
5 diff
(99.5 %id)
TI_1243022485   .a 2384 to 3488 1159 to 66       1096/1215
(90 %)
22 diff
(98.2 %id)
CR986439 T-Lymphocytes .a 2387 to 3247 1 to 861       861/861
(100 %)
0 diff
(100 %id)
BM905402 embryonal carcinoma, cell line, testis .a 2390 to 3348 9 to 972       964/995
(96 %)
39 diff
(96.1 %id)
CN272333 embryonic stem cells, DMSO-treated H9 cellline .a 2438 to 2912 1 to 475       475/485
(97 %)
2 diff
(99.6 %id)
DA674180   .a 2447 to 2850 186 to 589   capped   404/588
(68 %)
0 diff
(100 %id)
TI_1320132920   .a 2448 to 3488 1104 to 67       1038/1214
(85 %)
7 diff
(99.5 %id)
TI_1243022487   .a 2452 to 3488 1099 to 66       1034/1216
(85 %)
5 diff
(99.6 %id)
EC505241 Prostate .a 2454 to 2559 112 to 12   AAA   101/101
(100 %)
5 diff
(95.1 %id)
EC521021 Prostate .a 2465 to 2558 97 to 3       95/108
(87 %)
1 diff
(99.1 %id)
CN272343 embryonic stem cells, cell lines H1, H7, andH9 .a 2486 to 3234 1 to 749       749/749
(100 %)
3 diff
(99.6 %id)
BG391936 embryonal carcinoma, cell line, testis .a 2563 to 3333 1 to 766       766/880
(87 %)
19 diff
(97.9 %id)
CD652153 Embryonic Stem cells .a 2642 to 3413 12 to 782       771/831
(92 %)
17 diff
(98.0 %id)
BQ050685 leiomyosarcoma, uterus .a 2644 to 3556 1 to 928       928/1026
(90 %)
28 diff
(97.3 %id)
DB162734 thymus .a 2668 to 3238 2 to 572   capped   571/571
(100 %)
0 diff
(100 %id)
TI_154154749   .a 2697 to 3336 79 to 718       640/640
(100 %)
5 diff
(99.3 %id)
TI_1243018957   .a 2705 to 3488 1 to 782       782/1253
(62 %)
7 diff
(99.5 %id)
BG117307 adenocarcinoma, cell line, Liver .a 2727 to 3423 1 to 690       690/1088
(63 %)
13 diff
(98.9 %id)
CN272351 embryonic stem cells, cell lines H1, H7, andH9 .a 2740 to 3376 1 to 637       637/637
(100 %)
0 diff
(100 %id)
DB161741 thymus .a 2775 to 3338 11 to 576   capped   568/575
(98 %)
9 diff
(98.5 %id)
CN272329 embryonic stem cells, cell lines H1, H7, andH9 .a 2789 to 3497 1 to 710       710/710
(100 %)
1 diff
(99.9 %id)
BP331211 rectum .a 2799 to 3381 1 to 583       583/583
(100 %)
0 diff
(100 %id)
BP255534 Kidney .a 2831 to 3413 1 to 583       583/583
(100 %)
0 diff
(100 %id)
CN272339 embryonic stem cells, cell lines H1, H7, andH9 .a 2837 to 3389 1 to 553       553/553
(100 %)
0 diff
(100 %id)
BM477777 leiomyosarcoma, uterus .a 2842 to 3783 1 to 952       952/1017
(93 %)
21 diff
(98.0 %id)
AU129485   .a 2843 to 3516 2 to 675   capped   674/681
(98 %)
11 diff
(98.4 %id)
DB247868 uterus .a 2855 to 3419 2 to 566   capped   565/565
(100 %)
0 diff
(100 %id)
CN272340 embryonic stem cells, DMSO-treated H9 cellline .a 2863 to 3570 1 to 708       708/708
(100 %)
0 diff
(100 %id)
CD653192 Embryonic Stem cells .a 2867 to 3646 1 to 774       774/854
(90 %)
10 diff
(98.9 %id)
BG257346 embryonal carcinoma, cell line, testis .a 2902 to 3697 3 to 790       788/1180
(66 %)
15 diff
(98.8 %id)
DA505432 brain .a 2917 to 3462 2 to 547   capped   546/546
(100 %)
0 diff
(100 %id)
DA878230 Prostate .a 2919 to 3410 2 to 493   capped   492/492
(100 %)
0 diff
(100 %id)
AA450145   .a 2927 to 3367 1 to 440       440/440
(100 %)
1 diff
(99.8 %id)
DN601703 human embryonic stem cells .a 2931 to 3706 1 to 776       776/776
(100 %)
0 diff
(100 %id)
AU125461   .a 3022 to 3905 2 to 885   capped   884/891
(99 %)
11 diff
(98.8 %id)
CR982333 T-Lymphocytes .a 3065 to 3873 1 to 813       813/813
(100 %)
4 diff
(99.6 %id)
DB099493 testis .a 3105 to 3583 2 to 480   capped   479/479
(100 %)
0 diff
(100 %id)
BI039771 nervous_tumor .a 3159 to 3481 1 to 323       323/323
(100 %)
0 diff
(100 %id)
AW401693 lymph .a 3263 to 3656 1 to 394     Possibly primed on the genome, locally A rich (11/12 A in genome downstream of last aligned base) 394/394
(100 %)
5 diff
(98.8 %id)
TI_154137859   .a 3270 to 3845 74 to 653       580/580
(100 %)
12 diff
(98.0 %id)
TI_1243023359   .a 3273 to 3488 287 to 72       216/287
(75 %)
1 diff
(99.7 %id)
BG259614 embryonal carcinoma, cell line, testis .a 3280 to 4032 1 to 753       753/754
(99 %)
14 diff
(98.2 %id)
AA171577   .a 3400 to 3645 1 to 246       246/246
(100 %)
0 diff
(100 %id)
CN272337 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 3450 to 4016 1 to 567       567/567
(100 %)
0 diff
(100 %id)
BQ181680 Knee, Osteoarthritic Cartilage .a 3465 to 4065 617 to 17   AAA Possibly primed on the genome, locally A rich (11/11 A in genome downstream of last aligned base) 601/601
(100 %)
0 diff
(100 %id)
BQ614530 insulinoma, Pancreas .a 3468 to 3996 1 to 530       530/530
(100 %)
3 diff
(99.5 %id)
CK826330 insulinoma, Pancreas .a 3468 to 4042 1 to 576       576/576
(100 %)
3 diff
(99.5 %id)
ES309837 scalp interfollicular dermis, skin .a 3482 to 4009 1 to 525       525/525
(100 %)
9 diff
(98.3 %id)
AL040633 testis .a 3504 to 4065 585 to 24   AAA Possibly primed on the genome, locally A rich (11/11 A in genome downstream of last aligned base) 562/562
(100 %)
2 diff
(99.7 %id)
AU152319   .a 3527 to 4065 539 to 1       539/542
(99 %)
5 diff
(99.1 %id)
CB142396 Liver .a 3589 to 4037 1 to 449       449/449
(100 %)
0 diff
(100 %id)
TI_154136577   .a 3617 to 4408 848 to 59   AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 790/1171
(67 %)
37 diff
(96.9 %id)
AA889549   .a 3648 to 4065 434 to 17   AAA Possibly primed on the genome, locally A rich (11/11 A in genome downstream of last aligned base) 418/418
(100 %)
0 diff
(100 %id)
N46277 melanocyte .a 3653 to 3913 1 to 261   fully sequenced,   261/261
(100 %)
0 diff
(100 %id)
AA450088   .a 3680 to 4065 386 to 1       386/386
(100 %)
0 diff
(100 %id)
BQ439515 embryonal carcinoma, cell line, testis .a 3681 to 4544 1 to 867       867/872
(99 %)
9 diff
(99.0 %id)
CB126005 cervix, Uterine .a 3682 to 4294 1 to 613       613/613
(100 %)
0 diff
(100 %id)
AU128253   .a 3683 to 4303 2 to 622   capped   621/621
(100 %)
2 diff
(99.7 %id)
CX782071 human embryonic stem cells .a 3747 to 4549 1 to 804       804/804
(100 %)
1 diff
(99.9 %id)
CA395256 eye, RPE/choroid .a 3767 to 4234 1 to 468       468/468
(100 %)
0 diff
(100 %id)
BQ614314 insulinoma, Pancreas .a 3779 to 4408 646 to 16   tiling clone, AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 631/631
(100 %)
1 diff
(99.9 %id)
CX782755 human embryonic stem cells .a 3811 to 4633 1 to 824       824/824
(100 %)
1 diff
(99.9 %id)
CK826329 insulinoma, Pancreas .a 3825 to 4355 524 to 1       524/524
(100 %)
9 diff
(98.3 %id)
BU935255 mixed (pool of 40 RNAs) .a 3853 to 4623 1 to 782       782/793
(98 %)
22 diff
(97.3 %id)
N36960 melanocyte .a 3883 to 4408 518 to 1   fully sequenced,   518/518
(100 %)
10 diff
(98.1 %id)
T31467 colon, embryo .a 3917 to 4311 1 to 395       395/395
(100 %)
0 diff
(100 %id)
BM826215 Ascites, stomach .a 3922 to 4233 1 to 312       312/312
(100 %)
0 diff
(100 %id)
BQ425654 eye, retinoblastoma .a 3924 to 4758 17 to 859       843/867
(97 %)
14 diff
(98.4 %id)
TI_157598817   .a 3932 to 4408 580 to 99   AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 482/600
(80 %)
14 diff
(97.7 %id)
BF812619 colon_ins .a 3945 to 4055 111 to 1     Submitted on the opposite strand 111/111
(100 %)
0 diff
(100 %id)
TI_149279802   .a 3946 to 4408 520 to 57   AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 464/1160
(40 %)
4 diff
(99.7 %id)
BQ719996 sympathetic trunk .a 3990 to 4808 1 to 829       829/900
(92 %)
21 diff
(97.7 %id)
CX872723 embryonic stem .a 4050 to 4825 1 to 777       777/777
(100 %)
1 diff
(99.9 %id)
CX787967 human embryonic stem cells .a 4095 to 4878 1 to 785       785/785
(100 %)
2 diff
(99.8 %id)
CX166421 human embryonic stem cells differentiated toan early endodermal cell type .a 4174 to 5006 1 to 834       834/834
(100 %)
1 diff
(99.9 %id)
BG289214 bladder, transitional cell papilloma, cell line .a 4210 to 5023 1 to 809       809/892
(90 %)
37 diff
(95.9 %id)
BM558845 eye, retinoblastoma .a 4319 to 5198 1 to 896       896/1057
(84 %)
23 diff
(97.9 %id)
BX483507   .a 4349 to 4869 1 to 521       521/521
(100 %)
0 diff
(100 %id)
AA361881   .a 4361 to 4661 1 to 301       301/301
(100 %)
0 diff
(100 %id)
BM454770 leiomyosarcoma, uterus .a 4441 to 5339 13 to 924       912/1120
(81 %)
42 diff
(96.3 %id)
BG531978 embryonal carcinoma, testis .a 4468 to 5341 1 to 873       873/878
(99 %)
38 diff
(95.7 %id)
FN053342 breast carcinoma .a 4484 to 4611 129 to 1     Submitted on the opposite strand 129/129
(100 %)
2 diff
(98.5 %id)
BG527162 lung, mucoepidermoid carcinoma .a 4511 to 5404 1 to 884       884/925
(95 %)
43 diff
(95.4 %id)
BG400463 Kidney .a 4529 to 5374 1 to 832       832/869
(95 %)
19 diff
(97.9 %id)
BF111089 carcinoid, lung .a 4532 to 5070 539 to 1       539/539
(100 %)
0 diff
(100 %id)
BG612944 embryonal carcinoma, testis .a 4574 to 5375 1 to 809       809/812
(99 %)
21 diff
(97.5 %id)
BG392591 embryonal carcinoma, cell line, testis .a 4593 to 5346 1 to 752       752/955
(78 %)
26 diff
(97.3 %id)
BG499305 adenocarcinoma, Prostate .a 4636 to 5513 1 to 896       896/916
(97 %)
23 diff
(97.5 %id)
CN272328 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .a 4643 to 5401 1 to 759       759/759
(100 %)
2 diff
(99.8 %id)
AI905109 breast .a 4660 to 4765 1 to 106       106/106
(100 %)
0 diff
(100 %id)
BG742117 skin .a 4660 to 5506 1 to 850       850/850
(100 %)
16 diff
(98.2 %id)
BM464391 leiomyosarcoma, uterus .a 4663 to 5636 1 to 984   AAA   984/984
(100 %)
22 diff
(97.8 %id)
BE502359 pooled germ cell tumors .a 4671 to 5067 419 to 23   AAA Possibly primed on the genome, locally A rich (11/12 A in genome downstream of last aligned base) 397/397
(100 %)
0 diff
(100 %id)
FN099686 breast carcinoma .a 4676 to 4735 1 to 60       60/61
(98 %)
1 diff
(98.4 %id)
BP424168 small intestine .a 4688 to 5181 1 to 494     Submitted on the opposite strand 494/494
(100 %)
0 diff
(100 %id)
FN075282 breast carcinoma .a 4814 to 4887 76 to 1     Submitted on the opposite strand 76/77
(98 %)
2 diff
(97.5 %id)
TI_149291327   .a 4817 to 5632 891 to 86   AAA   806/912
(88 %)
13 diff
(98.6 %id)
CX782682 human embryonic stem cells .a 4862 to 5632 797 to 27   AAA   771/771
(100 %)
1 diff
(99.9 %id)
CB159300 Liver .a 4869 to 5517 1 to 649       649/649
(100 %)
0 diff
(100 %id)
AL041665 testis .a 4876 to 5092 1 to 217   fully sequenced,   217/217
(100 %)
0 diff
(100 %id)
BF340359 brain, glioblastoma with EGFR amplification .a 4882 to 5676 1 to 787       787/903
(87 %)
30 diff
(96.7 %id)
BG403272 bladder, transitional cell papilloma, cell line .a 4932 to 5438 1 to 507       507/507
(100 %)
0 diff
(100 %id)
TI_149298465   .a 4942 to 5632 759 to 83   AAA   677/760
(89 %)
19 diff
(97.5 %id)
BQ448161 Knee, Osteoarthritic Cartilage .a 4946 to 5632 703 to 17   AAA   687/687
(100 %)
1 diff
(99.9 %id)
FN125056 breast carcinoma .a 5010 to 5141 129 to 1     Submitted on the opposite strand 129/129
(100 %)
4 diff
(96.9 %id)
TI_151798151   .a 5017 to 5618 78 to 688       611/685
(89 %)
17 diff
(97.6 %id)
DB363086   .a 5045 to 5632 589 to 1       589/589
(100 %)
8 diff
(98.7 %id)
AL041666 testis .a 5062 to 5589 528 to 1   fully sequenced,   528/528
(100 %)
0 diff
(100 %id)
BI064318 uterus_tumor .a 5111 to 5602 1 to 492       492/492
(100 %)
0 diff
(100 %id)
DB366771   .a 5124 to 5632 509 to 1       509/509
(100 %)
8 diff
(98.5 %id)
DB365417   .a 5175 to 5761 583 to 1       583/585
(99 %)
10 diff
(98.3 %id)
AI436181 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .a 5201 to 5630 430 to 1       430/430
(100 %)
0 diff
(100 %id)
BQ380668 uterus_tumor .a 5205 to 5600 396 to 1       396/396
(100 %)
0 diff
(100 %id)
AW574556 lymph .a 5210 to 5761 569 to 18   AAA Possibly primed on the genome, locally A rich (11/12 A in genome downstream of last aligned base) 552/552
(100 %)
0 diff
(100 %id)
BM983197 lung, Primary Lung Cystic Fibrosis EpithelialCells .a 5211 to 5632 438 to 17   AAA   422/422
(100 %)
0 diff
(100 %id)
AW236479 pooled germ cell tumors .a 5213 to 5632 420 to 1       420/420
(100 %)
0 diff
(100 %id)
AI417171 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .a 5220 to 5632 413 to 1       413/413
(100 %)
0 diff
(100 %id)
AA926978 pooled .a 5242 to 5630 412 to 24   AAA   389/389
(100 %)
0 diff
(100 %id)
AA609764   .a 5243 to 5632 405 to 16   AAA   390/390
(100 %)
0 diff
(100 %id)
FN066351 breast carcinoma .a 5315 to 5438 128 to 1     Submitted on the opposite strand 128/128
(100 %)
4 diff
(96.9 %id)
AA987830 Kidney, kidney tumor .a 5324 to 5632 331 to 23   AAA   309/309
(100 %)
0 diff
(100 %id)
AI570851 adenocarcinoma, Pancreas .a 5340 to 5622 283 to 1       283/283
(100 %)
0 diff
(100 %id)
BF224308 carcinoid, lung .a 5365 to 5623 1 to 259     Submitted on the opposite strand 259/259
(100 %)
0 diff
(100 %id)
EC456877 Prostate .a 5374 to 5493 1 to 120       120/120
(100 %)
0 diff
(100 %id)
AI560080 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .a 5425 to 5633 209 to 1       209/209
(100 %)
0 diff
(100 %id)
AI885909 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus .a 5540 to 5622 83 to 1       83/83
(100 %)
0 diff
(100 %id)
AW149246 Kidney, renal cell tumor .a 5540 to 5622 83 to 1       83/83
(100 %)
2 diff
(97.6 %id)
AA780983   .a 5686 to 5761 92 to 17   AAA Possibly primed on the genome, locally A rich (11/12 A in genome downstream of last aligned base) 76/76
(100 %)
0 diff
(100 %id)
AK302541 testis .b 1 to 3822 9 to 3830 K663R tiling clone,   3822/3822
(100 %)
2 diff
(100.0 %id)
DC400989 testis .b 1 to 527 9 to 538       530/530
(100 %)
3 diff
(99.5 %id)
AU127139   .b 3566 to 4110 2 to 547   capped   546/546
(100 %)
4 diff
(99.3 %id)
Z43024 brain, total brain .b 3632 to 3921 1 to 290       290/290
(100 %)
0 diff
(100 %id)
BM722621 eye, fetal eye .b 3819 to 4454 1 to 637   tiling clone,   637/637
(100 %)
1 diff
(99.9 %id)
CR590211 placenta .b 4402 to 5519 1 to 1118   tiling clone,   1118/1118
(100 %)
0 diff
(100 %id)
BX459107 placenta .b 4402 to 5458 1 to 1041       1041/1053
(98 %)
21 diff
(98.1 %id)
BX434364 placenta .b 4628 to 5514 893 to 1       893/893
(100 %)
11 diff
(98.8 %id)
TI_154045238   .b 4643 to 5518 950 to 93   AAA   858/990
(86 %)
40 diff
(96.0 %id)
TI_149289749   .b 4699 to 5518 894 to 87   AAA   808/985
(82 %)
21 diff
(97.9 %id)
TI_149296766   .b 4709 to 5518 884 to 86   AAA   799/799
(100 %)
19 diff
(97.7 %id)
TI_154135657   .b 4763 to 5518 870 to 120   AAA   751/785
(95 %)
38 diff
(95.2 %id)
TI_149311041   .b 4790 to 5476 739 to 56       684/1029
(66 %)
0 diff
(100 %id)
CN479596 Chondrosarcoma, Left Pubic Bone .b 4802 to 5518 733 to 19   AAA   715/719
(99 %)
2 diff
(99.8 %id)
BI260846 cervical carcinoma cell line, cervix .b 4804 to 5579 1 to 779   tiling clone,   779/779
(100 %)
11 diff
(98.6 %id)
TI_154137021   .b 4818 to 5518 799 to 94   AAA   706/1218
(57 %)
16 diff
(98.7 %id)
AA024952 heart .b 4954 to 5112 1 to 161   fully sequenced,   161/161
(100 %)
0 diff
(100 %id)
BM679268 eye, fetal eye .b 4972 to 5517 565 to 19   AAA   547/547
(100 %)
1 diff
(99.9 %id)
BU737333 eye, fetal eyes .b 4982 to 5518 555 to 19   AAA   537/537
(100 %)
0 diff
(100 %id)
AA701911 liver and spleen .b 5023 to 5523 501 to 1       501/501
(100 %)
0 diff
(100 %id)
AI803067 pooled .b 5037 to 5519 483 to 1       483/483
(100 %)
0 diff
(100 %id)
AA024996 heart .b 5082 to 5519 438 to 1   fully sequenced,   438/438
(100 %)
0 diff
(100 %id)
BF221495 pooled germ cell tumors .b 5096 to 5518 423 to 1       423/423
(100 %)
0 diff
(100 %id)
AA972925 pooled .b 5145 to 5518 374 to 1       374/374
(100 %)
0 diff
(100 %id)
BX451907 placenta .b 5158 to 5519 1 to 356       356/356
(100 %)
6 diff
(98.4 %id)
AA732501 germinal center B cell .b 5217 to 5518 331 to 30   AAA   302/302
(100 %)
0 diff
(100 %id)
DB363931   .b 5250 to 5518 269 to 1       269/270
(99 %)
2 diff
(99.3 %id)
Z39126 brain, total brain .b 5280 to 5518 239 to 1       239/244
(97 %)
0 diff
(100 %id)
DB090008 testis .c 1 to 559 8 to 567   tiling clone, capped   560/560
(100 %)
3 diff
(99.5 %id)
DA404088 thalamus .c 467 to 1017 2 to 552   tiling clone, capped   551/551
(100 %)
0 diff
(100 %id)
DA390591 thalamus .c 943 to 1506 2 to 565   tiling clone, capped   564/564
(100 %)
0 diff
(100 %id)
BI026831 marrow .c 1209 to 1597 21 to 408   tiling clone,   388/408
(95 %)
7 diff
(98.3 %id)
BX095375 breast .d 1 to 607 1 to 607   tiling clone, AAA   607/607
(100 %)
0 diff
(100 %id)
BM914605 Spleen .d 191 to 860 1 to 674   tiling clone,   674/967
(69 %)
15 diff
(98.5 %id)
AA505298 breast .d 286 to 607 322 to 1       322/322
(100 %)
1 diff
(99.7 %id)
DC406802 thymus .d 611 to 1228 1 to 618   tiling clone,   620/620
(100 %)
0 diff
(100 %id)
BX441050 brain, fetal brain .d 733 to 1536 1 to 804 exact tiling clone,   804/804
(100 %)
1 diff
(99.9 %id)
AI914139 carcinoid, lung .e 1 to 461 1 to 461 K141X tiling clone, Submitted on the opposite strand 461/462
(99 %)
2 diff
(99.6 %id)
BP270707 small intestine .f-u 1 to 581 3 to 583 exact     583/583
(100 %)
0 diff
(100 %id)
BP270726 small intestine .f-u 1 to 582 3 to 584 exact tiling clone,   584/584
(100 %)
0 diff
(100 %id)
BF821498 kidney_tumor .f-u 76 to 656 1 to 577   tiling clone,   577/591
(97 %)
9 diff
(98.5 %id)
AI560272 anaplastic oligodendroglioma, brain .g 1 to 418 418 to 1 A2P G6X G7X G8A A23X tiling clone,   418/418
(100 %)
3 diff
(99.3 %id)
BG222410 normal squamous epithelium, tongue .g 197 to 418 1 to 222   AAA Possibly primed on the genome, locally A rich (11/11 A in genome downstream of last aligned base) 222/222
(100 %)
5 diff
(97.8 %id)
DB077734 testis .h 1 to 455 110 to 564 exact tiling clone, capped   455/563
(80 %)
6 diff
(99.0 %id)
DR002955 fetal brain .i 269 to 625 285 to 641 exact tiling clone,   641/641
(100 %)
7 diff
(99.0 %id)
DA907617   .j 1 to 562 2 to 566 A106C V107S tiling clone, capped   565/565
(100 %)
4 diff
(99.3 %id)
DA565666 heart .k 1 to 567 2 to 568 exact tiling clone, capped   567/567
(100 %)
1 diff
(99.9 %id)
BF115778 carcinoid, lung .l-u 1 to 385 388 to 1 exact tiling clone,   388/388
(100 %)
4 diff
(99.0 %id)
BF510256   .l-u 28 to 381 371 to 18   tiling clone, AAA Possibly primed on the genome, locally A rich (11/11 A in genome downstream of last aligned base) 354/354
(100 %)
0 diff
(100 %id)
BF855091 prostate_normal .m-u 1 to 270 1 to 269 I10F S11L D12I F13C V14F ... tiling clone,   269/277
(97 %)
8 diff
(97.2 %id)
BF855077 prostate_normal .m-u 7 to 270 1 to 264   tiling clone,   264/272
(97 %)
7 diff
(97.5 %id)
TI_1320132914   Gene SMARCC1, variant not shown         This clone was ignored    
TI_1320133243   Gene SMARCC1, variant not shown         This clone was ignored    
BE797876 lung, small cell carcinoma Gene SMARCC1, variant not shown         This clone was ignored    
TI_57200765   Gene SMARCC1, variant not shown         Suspected internal deletion, this clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f-u, .g, .h, .i, .j, .k, .l-u, .m-u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes CI